Peak Bio (PKBO)

Company Profile

Peak Bio Co., Ltd. is a clinical-stage biopharmaceutical company focused on developing therapeutics addressing significant unmet needs in the areas of oncology and inflammation. Peak Bio’s management team has a combined 50 years of industry experience in the areas of small molecules, antibodies, and antibody-drug-conjugates (ADC), forging successful companies that create differentiated cancer and immunological based therapeutics.

Company profile

Ticker

PKBO

Exchange

Incorporated

Location

Fiscal year end

Sector

Professional, Scientific, and Technical Services > Research and Development in Biotechnology

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Exelixis • Ginkgo Bioworks ...

Former names

Ignyte Acquisition Corp.

SEC CIK

0001834645

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

852448157

PKBO stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

S-1/A

IPO registration (amended)

31 Jan 23

8-K

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

9 Jan 23

S-1/A

IPO registration (amended)

4 Jan 23

8-K

Entry into a Material Definitive Agreement

Index to Carve-out Condensed Consolidated Financial Statements

Notice of late quarterly filing

14 Nov 22

8-K

Carve-out Condensed Consolidated Financial Statements

7 Nov 22

8-K

Entry into a Material Definitive Agreement

2 Nov 22

Latest ownership filings

View all

SC 13G/A

FROST PHILLIP MD ET AL

3 Feb 23

Peter David McCabe

18 Jan 23

Timothy M. Cunningham

Financial summary

Financial statements Chart PKBO financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	75.97 k	75.97 k	75.97 k	75.97 k	75.97 k	75.97 k
Cash burn (monthly)	(no burn)	37.77 k	224.74 k	205.10 k	57.00 k	57.84 k
Cash used (since last report)	n/a	162.43 k	966.53 k	882.07 k	245.15 k	248.73 k
Cash remaining	n/a	-86.46 k	-890.55 k	-806.10 k	-169.17 k	-172.76 k
Runway (months of cash)	n/a	-2.3	-4.0	-3.9	-3.0	-3.0

Beta Read what these cash burn values mean

Financial data from Peak Bio earnings reports.

Institutional ownership, Q3 2022

PKBO institutional ownership history Ownership history

79.9% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	44	45	-2.2%
Opened positions	5	6	-16.7%
Closed positions	6	3	+100.0%
Increased positions	4	19	-78.9%
Reduced positions	21	7	+200.0%

13F shares	Current	Prev Q	Change
Total value	58.06 mm	55.70 mm	+4.2%
Total shares	5.82 mm	6.80 mm	-14.4%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Deerfield Management	725.00 k	$7.24 mm	-33.3%
Flynn James E	725.00 k	$7.06 mm	0.0%
Phillip MD Frost Et Al	450.00 k	$4.64 mm	0.0%
Vellar Opportunities Fund Master	409.63 k	$4.06 mm	NEW
WRB W.R. Berkley	370.50 k	$3.70 mm	+8.9%
Saba Capital Management	368.43 k	$3.68 mm	0.0%
Cubist Systematic Strategies	263.07 k	$2.63 mm	+10.8%
Davidson Kempner Capital Management	225.23 k	$2.25 mm	-28.0%
Hudson Bay Capital Management	200.00 k	$2.00 mm	0.0%
D. E. Shaw & Co.	193.37 k	$1.93 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
K2 Principal Fund	0.00	-441.41 k	EXIT
Vellar Opportunities Fund Master	409.63 k	+409.63 k	NEW
Deerfield Management	725.00 k	-362.50 k	-33.3%
Meteora Capital	0.00	-200.84 k	EXIT
Davidson Kempner Capital Management	225.23 k	-87.65 k	-28.0%
Exos TFP	66.34 k	+66.34 k	NEW
Periscope Capital	165.03 k	-62.74 k	-27.5%
Spartan Fund Management	0.00	-60.69 k	EXIT
Mint Tower Capital Management B.V.	56.22 k	+56.22 k	NEW
Karpus Management	89.05 k	-50.00 k	-36.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Why Bed Bath & Beyond Shares Are Trading Higher By 17%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

10 Jan 23

Gainers

12 Health Care Stocks Moving In Tuesday's Intraday Session

10 Jan 23

Stocks That Hit 52-Week Lows On Tuesday

10 Jan 23

Tuesday's session saw 16 companies set new 52-week lows.

Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session

9 Jan 23

12 Health Care Stocks Moving In Monday's Intraday Session

9 Jan 23